sulfamethoxazole brands

33 registered brands containing sulfamethoxazole in Zambia.

sulfamethoxazole

PubChem CID 5329

Molecular formula: C10H11N3O3S

Sulfamethoxazole is a sulfonamide that inhibits bacterial dihydrofolic acid synthesis due to its structural similarity to an endogenous substrate, para-aminobenzoic acid (PABA). Most bacteria meet their need for folic acid by synthesizing it from PABA, as opposed to Animalia that require exogenous folic acid sources. Sulfamethoxazole competitively inhibits dihydropteroate synthase, the enzyme responsible for bacterial conversion of PABA to dihydrofolic acid. Inhibition of this pathway prevents the synthesis of tetrahydrofolate and, ultimately, the synthesis of bacterial purines and DNA, resulting in a bacteriostatic effect. Sulfonamides are usually bacteriostatic in action. Sulfonamides interfere with the utilization of p-aminobenzoic acid (PABA) in the biosynthesis of tetrahydrofolic acid (the reduced form of folic acid) cofactors in susceptible bacteria. Sulfonamides are structural analogs of PABA and appear to interfere with PABA utilization by competitively inhibiting the enzyme dihydropteroate synthase, which catalyzes the formation of dihydropteroic acid (a precursor of tetrahydrofolic acid) from PABA and pteridine; however, other mechanism(s) affecting the biosynthetic pathway also may be involved. Compounds such as pyrimethamine and trimethoprim, which block later stages in the synthesis of folic acid, act synergistically with sulfonamides. Only microorganisms that synthesize their own folic acid are inhibited by sulfonamides; animal cells and bacteria which are capable of utilizing folic acid precursors or preformed folic acid are not affected by these drugs. The antibacterial activity of the sulfonamides is reportedly decreased in the presence of blood or purulent body exudates. /Sulfonamides/ /Sulfonamides inhibit bacterial growth by preventing para-aminobenzoic acid (PABA) from being incorporated/ into dihydropteroic acid, the immediate precursor of folic acid. Sensitive microorganisms are those that must synthesize their own folic acid; bacteria that can utilize preformed folate are not affected. Bacteriostasis induced by sulfonamides is counteracted by PABA competitively. Sulfonamides do not affect mammalian cells by this mechanism, since they require preformed folic acid and cannot synthesize it. /Sulfonamides/ Sulfonamides are broad-spectrum, bacteriostatic anti-infectives. They are structural analogs of para-aminobenzoic acid and competively inhibit a bacterial enzyme, dihydropteroate synthetase, that is responsible for incorporation of para-aminobenzoic acid into dihydrofolic acid. This blocks the synthesis of dihydrofolic acid and decreases the amount of metabolically active tetrahydrofolic acid, a cofactor for the synthesis of purines, thymidine, and DNA. /Sulfonamides/ The hydroxylamine and nitroso metabolites formed by N4-oxidation of sulfonamides are thought to be involved in the pathogenesis of idiosyncratic reactions to this class of drugs. Idiosyncratic reactions to sulfonamides are characterized by multisystemic toxicity, including hepatitis, nephritis, dermatitis, and blood dyscrasias (aplastic anemia, agranulocytosis). Previously it has been shown that cytochrome p-450 in the liver metabolizes sulfamethoxazole to its hydroxylamine metabolite. In this paper the N4-oxidation of sulfamethoxazole by activated monocytes and neutrophils (human and canine) to form sulfamethoxazole hydroxylamine and nitrosulfamethoxazole is reported. The presumed nitroso intermediate was not detected. Purified myeloperoxidase and prostaglandin H synthase were also capable of mediating the oxidation of sulfamethoxazole. The present studies suggest that myeloperoxidase is responsible for the observed oxidation by phagocytic cells. Oxidation by neutrophils may play a role in agranulocytosis, and oxidation by monocytes may facilitate antigen presentation. Extrahepatic bioactivation of sulfonamides by peroxidases in phagocytic cells and other tissues may be important in determining the range of adverse reactions to sulfonamides

Source: PubChem (NCBI) ยท compound 5329

Product Manufacturer Status Country
(Medoprim DS) Co-trimoxazole 960mg Tablets BP
Tablet Uncoated
Medopharm Registered/Compliant Zambia
Betrim tablets
Tablet Uncoated
Milan Laboratories Registered/Compliant Zambia
Biosol WDP
Water soluble powder
Vetcare Kenya Registered/Compliant Zambia
Bronquidiazina CR suspension
Suspension for Oral Use
Faes Farma Registered/Compliant Zambia
Co-trimoxazole
Tablets+ Filmcoated
Guilin Pharmaceuticals Registered/Compliant Zambia
Co-trimoxazole Padiatric Oral Suspension 240mg/5ml
Suspension for Oral Use
Ciron Drugs & Pharmaceuticals Registered/Compliant Zambia
Co-trimoxazole tablets
Tablet Uncoated
Missionparma Registered/Compliant Zambia
Compound Sulfamethoxazole
Tablet Uncoated
North China Pharmaceutical Co. Registered/Compliant Zambia
Cotrikant Oral suspension
Suspension for Oral Use
S Kant Healthcare Registered/Compliant Zambia
Cotrim 480 tablets
Tablet Uncoated
Vardhman Exports Registered/Compliant Zambia
Cotrimoxazole Oral suspension
Suspension for Oral Use
Lincoln Pharmaceuticals Registered/Compliant Zambia
Cotrimoxazole tablets
Tablet Uncoated
Micro Labs Registered/Compliant Zambia
Fartrim
Solution for Injection
Virbac Registered/Compliant Zambia
Kotrim suspension
Oral Suspension
Yash Life Sciences Registered/Compliant Zambia
Kotrim tablet
Tablet Uncoated
Yash Life Sciences Registered/Compliant Zambia
L-Trim Suspension
Suspension for Oral Use
Leben Laboratories Registered/Compliant Zambia
L-Trim Tablets
Tablet Uncoated
Leben Laboratories Registered/Compliant Zambia
Lecotrim
Tablet Uncoated
Laboratory And Allied Registered/Compliant Zambia
MEDOPRIM TABLETS
Tablet Uncoated
Medopharm Registered/Compliant Zambia
Megatrim suspension
Suspension for Oral Use
Fourrts Laboratories Registered/Compliant Zambia
Megatrim tablets
Tablet Uncoated
Fourrts Laboratories Registered/Compliant Zambia
Mims Co-trimoxazole suspension
Suspension for Oral Use
International Drug Company Registered/Compliant Zambia
ML Cotri Suspension (Paediatric Co-trimoxazole Oral Suspension)
Suspension for Oral Use
Milan Laboratories Registered/Compliant Zambia
Novatrim (Co-trimoxazole) Tablets
Tablet Uncoated
Pharmanova Registered/Compliant Zambia
Novatrim Suspension
Suspension for Oral Use
Pharmanova Registered/Compliant Zambia
Q-TIB Tablets
Tablet Uncoated
Cipla Registered/Compliant Zambia
Sulfatrim Forte Tablets
Tablet Uncoated
Shalina Laboratories Registered/Compliant Zambia
Sulfatrim susp
Suspension for Oral Use
Gopaldas Visram Registered/Compliant Zambia
Sulfran Paediatric suspension
Suspension for Oral Use
Universal Corporation Registered/Compliant Zambia
Sulphamethoxazole 800mg+ Trimethoprim 160mg USP tablets
Tablet Uncoated
Guilin Pharmaceutical Registered/Compliant Zambia
Trim 480 tablets
Tablet Uncoated
Kopran Registered/Compliant Zambia
Trimaprim tablets
Tablet Uncoated
Saga Lifesciences Registered/Compliant Zambia
Trimoxol Vet Oral Powder
Oral soluble powder
Medisel Kenya Registered/Compliant Zambia